Clinical Trial ResultsPositive data from the SPOTLIGHT study increase confidence in positive BEACON data, with a demonstrated dose response in efficacy and no safety concerns.
Market OpportunityThere is a meaningful opportunity with Jasper's briquilimab for patients not well controlled with antihistamines, targeting a significant number of patients in the US suffering from chronic urticaria.
Strategic DevelopmentsAnalyst is optimistic on Jasper's strategy to develop briquilimab for chronic spontaneous urticaria and chronic inducible urticaria with multiple studies underway.